Practice

GCA with normal CRP? French study of GCA > 50 yrs, dx w/ temp artery Bx 67% or imaging (US, PET) + nl Baseline CRP <10 mg/L. 74 pts (age 73 yrs) 84% filled 2022 Dx criteria. Low CRP pt had less fever, fatigue, wt loss, PMR Sxs & more ischemic Sxs and strokes. They were more https://t.co/olL8Vf93DW

Are clinical scenarios into AI chatbots useful? (both specialized eg OpenEvidence or generalist eg ChatGPT): performance will vary (platform but also model, effort) prompt structure critical users (patients & clinicians) need to know real limitations ABST0869 #ACR26 @RheumNow https://t.co/vPNvJlSXZY

Kim et al. Target trial emulation. Add on pulse steroids (to RTX or CYC) in AAV. No benefit and higher infection risk. @RheumNow #ACR26 Abstr#0929 https://t.co/RPtIiP0XLN

https://x.com/RichardPAConway/status/2119535431012262388/photo/1

@RheumNow Building bridges to better care: Advocacy and legislative updates in pediatrics #ACR2026 The AAP advocates for equitable access to care, science-based policies, fair reimbursement & pediatric workforce equity. Advocacy is stronger together!

Five AI platforms were tested on 60 ACR and EULAR based scenarios: guideline concordance ranged from 74.9% to 91.2% and hallucination rates from 3.8% to 18.1%. Key finding: clinically relevant errors occurred on every platform, and the authors recommend clinician oversight.

Can AI be trusted for clinical decisions in rheumatology? #ACR26 Abst 0869: Across 60 scenarios, guideline concordance reached 91.2% with OpenEvidence and 89.4% with ChatGPT. Hallucination rates: 3.8% and 6.2%. Promising tools, clinical oversight remains essential! @RheumNow https://t.co/mMdDULkw9U

https://x.com/Mota_licia_reum/status/2119468669478826271/video/1

Kreis et al. What to do after tocilizumab in GCA. MTX did not reduce time to relapse. Few secondary outcomes numerically lower with MTX. In my opinion, just continue the tocilizumab. @RheumNow #ACR26 Abstr#0179 https://t.co/E3uOnaxPmW

https://x.com/RichardPAConway/status/2119468740710404487/photo/1

Matute-Gajardo et al. Real world treatment choices in SARD-ILD. Seems like the ACR guidelines are not reflecting what rheumatologists do (rightly so in my opinion) @RheumNow #ACR26 Abstr#0470 https://t.co/sFfc1MtgTz

https://x.com/RichardPAConway/status/2119461694153916482/photo/1

AI advice in clinical decision support still needs checking. In 60 rheum scenarios, 5 platforms had hallucination rates of 3.8-18.1%. Dosing, treatment-selection and screening errors occurred across platforms, even those with high guideline concordance. #0869 @Rheumnow #ACR26

Univ Michigan cohort study by Dr. Baek et al showed serum HCQ levels of pts varied widely when given the same wt-based dose (eg. HCQ at 5mkd, fr 100-600ng/mL) Indepndnt assocs: Wt-based dose & eGFR w/sHCQ, lower eGFR w/higher sHCQ Monitor HCQ, eGFR levels @RheumNow #ACR26 ABS0270 https://t.co/lKLTShXIBb

https://x.com/RHEUMarampa/status/2119458674183930357/photo/1

Shared decision making is not just a 'nice to have' but how do we scale it? intervention with VA clinics: meds summary, patient activation brochure, conversation aid, clinician training result: oral adherence up 10% tools here: https://t.co/O3z4Fipp0G ABST0590 #ACR26 @RheumNow https://t.co/KGWEZJueWR

#Vaccinate your #SARD Pts esp if given strong #immune #suppression #Taiwan #College of #Rheumatology #recommendations for #vaccines Pre & Post #CAR-T Can apply for #IMMUNESUPPRESSED Pts in general who get #B #cell #depletion #ACR26 abst#2773 @RheumNow https://t.co/34xcBjsD99

https://x.com/Janetbirdope/status/2118361831509241883/photo/1

-AZA is safe in pregnancy but can cause risk of ICP. -Monitor pts on AZA closely for ICP symptoms. #ACR26 @RheumNow https://t.co/v9mNKVNKcm

https://x.com/AdelaCastro222/status/2119073335539912773/photo/1

Women's Health and Reproductive Issues: APLAR 2026 https://t.co/E3IjKP91qL https://t.co/imOGOjce83

Women's Health and Reproductive Issues: APLAR 2026 | RheumNow

Article

3 x IL-23 = IL do Better (11.6.2026)

Jack Cush, MD Nov 06, 2026

Dr. Jack Cush reviews the FDA approvals and news reports from this past week on RheumNow.com. This week we discuss playing the numbers in rheumatology, playing the long game with stem cell transplants, and a=the Positive spin on seronegative RA.

APLAR 2026: CAR T in Rheumatology: Promise or Peril? https://t.co/nw1iu7eCpn https://t.co/61Z2mn3vln

APLAR 2026: CAR T in Rheumatology: Promise or Peril? | RheumNow

APLAR 2026: The Rheumatologist and AI https://t.co/g81loiW0pI https://t.co/udiw3eoNJr

APLAR 2026: The Rheumatologist and AI | RheumNow

Article

The Concern about Seronegative RA

Jack Cush, MD Nov 03, 2026

A current review of seronegative RA (SNRA) by D’Onofrio, et al in npj Autoimmunity shows the diverse fate of seronegative RA - which can resolve, persist or become refractory. Clearly dedicated trials of SNRA are needed to better predict.

THe the International Federation of Psoriasis Associations has announced that the 8th World Psoriasis & Psoriatic Arthritis Conference will be taking place in Stockholm on 20–22 May 2027. Registration is open. https://t.co/lq5XdcZlki https://t.co/AYGCnwzeue https://t.co/fy6UUCbcxf

Lupus/LN should not be a sole indication for a C-section C-section should be reserved for obstetric indications. Adapt a multidisciplinary approach. @RheumNow #APLAR2026 https://t.co/vrXeNP9xLI

https://x.com/RHEUMarampa/status/2116726182029009040/photo/1

The growing unmet needs of repro health in the @APLAR_org region lead to dev’t of new consensus statements Provides a practical guide for rheums focusing on key areas like preconception, meds safety in pregnancy & men w/AIRDs planning to become fathers etc @RheumNow #APLAR2026 https://t.co/xCKmpcD4ma

Guidelines similar for GC use in pregnancy. For @APLAR_org , non-fluorinated gcs are recommended and much lower doses of prednisone <5mg/day as the target with IV MP preferred for severe disease. Universal recos to monitor BP, glucose and steroid-related SEs @RheumNow #APLAR https://t.co/FrQEsbLbOk

https://x.com/RHEUMarampa/status/2116922932379435196/photo/1

Article

FDA Approves Tildrakizumab for Psoriatic Arthritis

Jack Cush, MD Nov 02, 2026

Sun Pharmaceuticals announced Friday that the FDA has approved its IL-23 inhibitor, tildrakizumab (Ilumya) for use in patients with active psoriatic arthritis. This agent is already FDA approved for plaque psoriasis, and joins guselkumab and risankizumab as the third IL-23 inhibitor

An important and relevant reminder from @rheumarhyme on AI use @RheumNow #APLAR2026 https://t.co/7Ratb6aQOD

https://x.com/RHEUMarampa/status/2116369684358684894/photo/1

AI can be helpful in manuscript creation As the author: > always verify the draft - allow time to check > take full responsibility of the content - review and revise the final manuscript @RheumNow #APLAR2026 https://t.co/cQsEtDc7z1